Replies to post #724 on Abbvie Inc (ABBV)

[DewDiligence]

ABBV pipeline update:

https://investors.abbvie.com/static-files/9200a822-5d4b-4a1d-a4f3-720cb7b76723

[DewDiligence]

ABBV 4Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2023/02/09/abbvie-abbv-q4-2022-earnings-call-transcript/

[DewDiligence]

ABBV reports 1Q23 results—raises non-GAAP EPS guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2023-financial-results.htm

2023 non-GAAP EPS has been raised $0.10 at both the lower and upper bounds of the range, which is now $10.72-$11.12. This a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.